Stocks › RGEN
REPLIGEN CORP
RGEN·Nasdaq·
United States·USD
$163.81
-6.48 (-3.81%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
RGEN
REPLIGEN CORP · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RGENS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of RGEN by members of U.S. Congress · 8 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Sale $1,001 - $15,000 |
Nov 21, 2025 | Oct 31, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Sale $1,001 - $15,000 |
Nov 21, 2025 | Oct 30, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Purchase $1,001 - $15,000 |
Nov 21, 2025 | Oct 30, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Sale $1,001 - $15,000 |
Aug 13, 2025 | Jun 17, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Purchase $1,001 - $15,000 |
Aug 13, 2025 | Jul 22, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
RGENREPLIGEN CORP · Stock |
Purchase $1,001 - $15,000 |
Aug 13, 2025 | Jun 11, 2025 | Filing ↗ |
Jefferson ShreveHouse · R · IN |
RGENREPLIGEN CORP · Stock |
Sale $15,001 - $50,000 |
May 8, 2025 | Apr 7, 2025 | Filing ↗ |
Ro KhannaHouse · D · CA |
RGENREPLIGEN CORP · Common Stock |
Sale $1,001 - $15,000 |
Jan 7, 2022 | Dec 14, 2021 | Filing ↗ |
Whale Activity
Position changes in RGEN reported for 2026-09-30 by 575 institutional filers
- Increased186
- New100
- Held79
- Decreased136
- Closed50
- No prior filing24
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 7.4M | $1.41B | increased |
| BlackRock, Inc. | 5.7M | $1.10B | increased |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 2.8M | $536.3M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | $469.6M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.3M | $436.7M | decreased |
| Invesco Ltd. | 2.1M | $410.2M | increased |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.0M | $392.3M | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.0M | $390.3M | increased |
| STATE STREET CORP | 1.8M | $355.5M | increased |
| AMERIPRISE FINANCIAL INC | 1.7M | $324.7M | — |
| MAVERICK CAPITAL LTD | 1.4M | $272.5M | decreased |
| T. Rowe Price Investment Management, Inc. | 1.4M | $268.6M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by RGEN insiders, by quarter · Form 4
Recent Insider Transactions
1,099 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Loeillot OlivierChief Executive Officer · Director | Sale | −4,202 | $190.00 | $798K | Oct 5, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −1,333 | $178.75 | $238K | Oct 5, 2026 | Form 4 ↗ |
| Garland Jason KCFO | Tax withholding | −421 | $189.68 | $80K | Sep 25, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −4,542 | $190.00 | $863K | Sep 24, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Option exercise | +4,542 | $155.38 | $706K | Sep 24, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −8,404 | $190.00 | $1.6M | Sep 24, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Option exercise | +8,404 | $154.96 | $1.3M | Sep 24, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −5,426 | $180.00 | $977K | Sep 21, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Option exercise | +5,426 | $141.79 | $769K | Sep 21, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −3,035 | $165.90 | $504K | Sep 4, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Tax withholding | −2,842 | $169.61 | $482K | Sep 3, 2026 | Form 4 ↗ |
| Hughes ViolettaCHIEF ACCOUNTING OFFICER | Tax withholding | −277 | $170.02 | $47K | Sep 1, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Sale | −5,426 | $180.00 | $977K | Aug 20, 2026 | Form 4 ↗ |
| Loeillot OlivierChief Executive Officer · Director | Option exercise | +5,426 | $141.79 | $769K | Aug 20, 2026 | Form 4 ↗ |
| Garland Jason KCFO | Sale | −530 | $150.00 | $80K | Jul 16, 2026 | Form 4 ↗ |
| Garland Jason KCFO | Sale | −733 | $145.00 | $106K | Jun 25, 2026 | Form 4 ↗ |
| Konstantinov KonstantinDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| Madaus Martin DDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| EGLINTON MANNER CARRIEDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
| MUIR GLENN PDirector | Grant / award | +995 | $0.00 | $0 | May 14, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding RGEN · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF iShares Trust | 1.8M | $247.6M | 0.20% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.7M | $232.3M | 0.01% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund MFS Series Trust IV | 1.0M | $189.0M | 1.46% | Aug 31, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $167.7M | 0.09% | Jun 30, 2026 |
| Invesco Discovery Fund AIM Counselor Series Trust (Invesco Counselor Series Trust) | 817.9K | $148.0M | 2.00% | Aug 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 963.0K | $131.4M | 0.89% | Jun 30, 2026 |
| Select Health Care Portfolio Fidelity Select Portfolios | 570.0K | $103.2M | 1.53% | Aug 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 709.0K | $96.7M | 0.21% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund Fidelity Rutland Square Trust II | 515.3K | $93.3M | 0.04% | Aug 31, 2026 |
| Select Medical Technology and Devices Portfolio Fidelity Select Portfolios | 500.0K | $90.5M | 2.70% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list RGEN's shares (CUSIP 759916109), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 7.4M shares13.0%
Oct 7, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 7.4M shares13.0%
Oct 7, 2026 · ↗ - T. Rowe Price Associates, Inc.SCHEDULE 13G/A · passive (13G) · 1.8M shares3.1%
Aug 14, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 2.8M shares5.0%
Jul 31, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming REPLIGEN CORP as client
No lobbying filings found naming REPLIGEN CORP as the client.
Government Contracts
Federal awards to repligen · USAspending
$204KAwarded · 2 contracts on record
U.S. Patents
Recent USPTO applications naming REPLIGEN CORP
No USPTO patent applications found for REPLIGEN CORP.
Annual Financials
From RGEN's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | $55.2M | -$35.1M | $47.7M | $224.7M | $167.2M |
| Net income | $48.9M | -$25.5M | $35.6M | $186.0M | $128.3M |
| Diluted EPS | $0.86 | -$0.46 | $0.63 | $3.24 | $2.24 |
| Operating cash flow | $117.4M | $175.4M | $113.9M | $172.1M | $119.0M |
| Cash and equivalents | $566.0M | $757.4M | $751.3M | $523.5M | $603.8M |
| Total assets | $2.95B | $2.83B | $2.83B | $2.52B | $2.36B |
| Total liabilities | $843.6M | $856.9M | $866.3M | $614.0M | $608.3M |
| Shareholders' equity | $2.11B | $1.97B | $1.96B | $1.91B | $1.75B |
As REPLIGEN CORP tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in RGEN's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01, 2.03, 3.02, 9.01Material agreement · Direct financial obligation · Unregistered sale of equityNov 6, 2026
EDGAR ↗ - 8-K · Items 3.02, 8.01, 9.01Unregistered sale of equity · Other eventsOct 30, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsOct 27, 2026
EDGAR ↗ - 8-K · Items 2.01, 7.01, 9.01Acquisition or disposition · Reg FD disclosureOct 6, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeSep 15, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 28, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.02, 7.01, 8.01, 9.01Material agreement · Results of operations · Reg FD disclosureJul 22, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 15, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About REPLIGEN CORP
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersWALTHAM, MA
IncorporatedDE
SEC CIK0000730272 ↗



